1. Scrip
  2. >>New Products

Could Cash-Strapped Idorsia Really Go It Alone With Newly Approved Tryvio?

 
• By Andrew McConaghie

CEO Jean-Paul Clozel insists Idorsia could launch the first-in-class hypertension drug alone, but analysts think a deal will be done soon – with the only question being for how much.

Idorsia building

Idorsia is celebrating US approval of its first-in-class hypertension treatment Tryvio – but the cash-strapped company may well have to sell off the rights to the product in order to keep its debtors at bay.

CEO and founder Jean Paul Clozel told Scrip that the company was still reviewing its options, and remains committed to launching the drug in the US before the end

Key Takeaways

  • Idorsia has just gained its second US drug approval – but has just a few months of cash runway left

  • The company has confirmed licensing interest in Tryvio, but

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

 
• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.

Pipeline Watch: Eight Approvals And Nineteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Trump’s executive order more rhetoric than action; industry grapples with Trump pricing plan; Hengrui set for this year’s biggest IPO; Sanofi’s exec’s advice to biotechs; and biotech deal return on investment falls.